Govardhan Dhoot

Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”

Pending orders may boost revenues 15-20% in FY17: Mangalam Drugs

Govardhan Dhoot, MD, Mangalam Drugs & Organics is confident of improving revenues and growing by 15-20 percent over the last fiscal on back of pending orders.

Mangalam Drugs plans to enter HIV API space

Drugs for ailments like malaria and HIV are well-accepted in the market and it'll be an advantage for Mangalam Drugs, says Managing Director Govardhan Dhoot.

Looking to hike stake in company to 52%: Mangalam Drugs

Mangalam Drugs' has fallen 37 percent since its high in December 8, 2015 and has been in lower circuit for the past 7 sessions.

See 11% plus margins by yr-end: Mangalam Drugs Organic

Govardhan Dhoot, MD, Mangalam Drugs Organic, details his company's performance in the second quarter.